Assessment of efficacy and safety of the herbal medicinal product BNO 1016 in chronic rhinosinusitis
Palm J, Steiner I, Abramov-Sommariva D, Ammendola A, Mitzenheim S, Steindl H, Kreindl C, Bachert C
Published in Rhinology
Methodology
Randomized placebo-controlled trial of two doses of BNO 1016 (containing gentian root) in 929 patients with chronic rhinosinusitis over 12 weeks.
Key Findings
Neither dose met the primary endpoint: symptom improvement in chronic rhinosinusitis did not differ significantly from placebo.
Conclusions
The gentian-containing herbal combination is not effective for chronic rhinosinusitis, despite benefit in acute disease.
Limitations
Multi-herb product; high placebo response; chronic disease heterogeneity.
Supplements Studied
Neither dose of the gentian-containing herbal product met the primary endpoint in chronic rhinosinusitis.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.